0001209191-23-010972.txt : 20230217 0001209191-23-010972.hdr.sgml : 20230217 20230217213113 ACCESSION NUMBER: 0001209191-23-010972 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230215 FILED AS OF DATE: 20230217 DATE AS OF CHANGE: 20230217 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: McKenna Mark C. CENTRAL INDEX KEY: 0001749623 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40187 FILM NUMBER: 23645032 MAIL ADDRESS: STREET 1: 400 SOMERSET CORPORATE BOULEVARD CITY: BRIDGEWATER STATE: NJ ZIP: 08807 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Prometheus Biosciences, Inc. CENTRAL INDEX KEY: 0001718852 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 814282653 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 3050 SCIENCE PARK ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: (858) 422-4300 MAIL ADDRESS: STREET 1: 3050 SCIENCE PARK ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: Precision IBD, Inc. DATE OF NAME CHANGE: 20171004 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2023-02-15 0 0001718852 Prometheus Biosciences, Inc. RXDX 0001749623 McKenna Mark C. C/O PROMETHEUS BIOSCIENCES, INC. 3050 SCIENCE PARK ROAD SAN DIEGO CA 92121 1 1 0 0 Chairman, President & CEO Common Stock 2023-02-15 4 M 0 25000 2.90 A 80144 D Common Stock 2023-02-15 4 S 0 25000 119.42 D 55144 D Common Stock 2023-02-16 4 M 0 25000 3.70 A 80144 D Common Stock 2023-02-16 4 S 0 25000 119.87 D 55144 D Common Stock 2023-02-17 4 M 0 13680 3.70 A 68824 D Common Stock 2023-02-17 4 S 0 13680 125.10 D 55144 D Stock Option (Right to Buy) 2.90 2023-02-15 4 M 0 25000 0.00 D 2029-11-06 Common Stock 25000 308633 D Stock Option (Right to Buy) 3.70 2023-02-16 4 M 0 25000 0.00 D 2030-12-17 Common Stock 25000 506725 D Stock Option (Right to Buy) 3.70 2023-02-17 4 M 0 13680 0.00 D 2030-12-17 Common Stock 13680 493045 D The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person. The price reported in Column 4 is a weighted average price. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price. 25% of the shares subject to the option vested and became exercisable on September 9, 2020, and 1/48th of the shares subject to the option shall vest monthly thereafter, subject to the Report Person's continued service with the Issuer through each vest date. 25% of the shares subject to the option vested and became exercisable on November 5, 2021, and 1/48th of the shares subject to the option shall vest monthly thereafter, subject to the Report Person's continued service with the Issuer through each vest date. /s/ Timothy K. Andrews, attorney-in-fact for Mark C. McKenna 2023-02-17